Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Revelation Biosciences, Inc. (REVB : NSDQ)

• Company Description    Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $0.57 Daily Weekly Monthly 20 Day Moving Average: 331,596 shares Shares Outstanding: 15.08 (millions) Market Capitalization: $8.55 (millions) Beta: 2.70 52 Week High: $11.29 52 Week Low: $0.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -55.70% -50.11% 12 Week -67.23% -63.97% Year To Date -94.44% -92.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4660 LAJOLLA VILLAGE DRIVE SUITE 100 - SAN DIEGO,CA 92122 USA ph: 650-800-3717 fax: - None http://www.revbiosciences.com

• General Corporate Information    Officers James Rolke - Chief Executive Officer George Tidmarsh - Chairman Chester S. Zygmont - Chief Financial Officer Jennifer Carver - Director Jess Roper - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76135L101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 15.08 Most Recent Split Date: (:1) Beta: 2.70 Market Capitalization: $8.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -12.04 12/31/21 - -3.16 09/30/21 - -3.43 Current Ratio 03/31/22 - 0.97 12/31/21 - 0.02 09/30/21 - 0.01 Quick Ratio 03/31/22 - - 12/31/21 - 0.02 09/30/21 - 0.01 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - -0.01 12/31/21 - -4.30 09/30/21 - -0.73 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©